rawfin.tv
Cabaletta Bio Doses Patients with rese-cel CAR T Therapy Using Cellares Technology
TechnologystocksAI Generated

Cabaletta Bio Doses Patients with rese-cel CAR T Therapy Using Cellares Technology

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Cellares announced that the first two patients have received doses of Cabaletta Bio's investigational CAR T cell therapy, rese-cel. The therapy was manufactured using Cellares' Cell Shuttle platform.

BiotechCAR T TherapyClinical TrialsPharmaceuticalsCell Therapy

Related Articles

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks
Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

stocks
Ambarella Gains as Nvidia Emerges as Potential Third Bidder

Ambarella Gains as Nvidia Emerges as Potential Third Bidder

stocks
SpaceX and Tesla Boards Review Potential $3.5 Trillion Merger

SpaceX and Tesla Boards Review Potential $3.5 Trillion Merger

stocks